JP2009544688A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544688A5
JP2009544688A5 JP2009521380A JP2009521380A JP2009544688A5 JP 2009544688 A5 JP2009544688 A5 JP 2009544688A5 JP 2009521380 A JP2009521380 A JP 2009521380A JP 2009521380 A JP2009521380 A JP 2009521380A JP 2009544688 A5 JP2009544688 A5 JP 2009544688A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
fusion polypeptide
phospholipase
ptd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521380A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544688A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2007/003404 external-priority patent/WO2008015580A2/en
Publication of JP2009544688A publication Critical patent/JP2009544688A/ja
Publication of JP2009544688A5 publication Critical patent/JP2009544688A5/ja
Pending legal-status Critical Current

Links

JP2009521380A 2006-07-24 2007-07-19 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法 Pending JP2009544688A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83258406P 2006-07-24 2006-07-24
PCT/IB2007/003404 WO2008015580A2 (en) 2006-07-24 2007-07-19 Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same

Publications (2)

Publication Number Publication Date
JP2009544688A JP2009544688A (ja) 2009-12-17
JP2009544688A5 true JP2009544688A5 (enExample) 2010-08-05

Family

ID=38997534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521380A Pending JP2009544688A (ja) 2006-07-24 2007-07-19 虚血性疾患の緩和及び治療のための医薬組成物並びにそれを伝達するための方法

Country Status (6)

Country Link
US (1) US7902154B2 (enExample)
EP (1) EP2044108A4 (enExample)
JP (1) JP2009544688A (enExample)
KR (1) KR101574630B1 (enExample)
CN (1) CN101490080A (enExample)
WO (1) WO2008015580A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416383B2 (en) * 2007-04-27 2016-08-16 University Of North Carolina At Chapel Hill Method for enhancing catalytic activity of a lipase
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
CN101612384B (zh) * 2009-07-23 2012-06-20 中国人民解放军第二军医大学 多肽小分子mlif在制备防治心肌缺血药物中的应用
KR101278221B1 (ko) * 2010-06-01 2013-06-24 연세대학교 산학협력단 Ρtd-uqcrb 융합 폴리펩타이드 및 그를 포함하는 허혈성 질환의 예방 및 치료용 약제학적 조성물
KR101873773B1 (ko) 2012-05-11 2018-08-02 주식회사 젬백스앤카엘 류마티즘 관절염 예방 또는 치료 조성물
CN108841802B (zh) 2012-05-11 2023-06-09 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
JP6272853B2 (ja) 2012-07-11 2018-01-31 ジェムバックス アンド カエル カンパニー,リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
WO2014171792A1 (ko) 2013-04-19 2014-10-23 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
EP4063863A1 (en) 2013-06-07 2022-09-28 Gemvax & Kael Co., Ltd. Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients
CN105324123B (zh) 2013-06-21 2022-02-08 珍白斯凯尔有限公司 激素分泌调节剂、包含该调节剂的组合物、和利用其控制激素分泌的方法
EP3072519B1 (en) 2013-11-22 2020-08-19 Gemvax & Kael Co., Ltd. Peptide having angiogenesis inhibitory activity and composition containing same
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
ES2908096T3 (es) 2014-04-11 2022-04-27 Gemvax & Kael Co Ltd Péptido con actividad inhibidora de la fibrosis y composición que lo contiene
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
WO2015167067A1 (ko) * 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
JP6923453B2 (ja) 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー,リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
WO2017176087A1 (ko) 2016-04-07 2017-10-12 주식회사 젬백스앤카엘 텔로머라제 활성 증가 및 텔로미어 연장 효능을 가지는 펩티드 및 이를 포함하는 조성물
KR20250057224A (ko) 2023-10-19 2025-04-29 단국대학교 천안캠퍼스 산학협력단 Pdrn을 이용한 유치줄기세포를 포함하는 세포치료제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166191A (en) * 1996-08-23 2000-12-26 Chiron Corporation Human polyhomeotic 1(HPH1) acts as an oncogene
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 mph1-btm 및 이것을포함하는 생명공학제품
KR20030062789A (ko) 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 sim2-btm 및 이것을포함하는 생명공학제품
KR100591936B1 (ko) 2002-11-12 2006-06-22 포휴먼텍(주) 세포내 dna/rna 전달 방법, 및 이것의 기초 및임상학적 응용
US7166692B2 (en) * 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
ZA200509229B (en) * 2003-05-01 2007-03-28 Cornell Res Foundation Inc Method and carrier complexes for delivering molecules to cells
WO2004113497A2 (en) * 2003-06-09 2004-12-29 University Of Florida Gene delivery to tumors
US7723299B2 (en) * 2005-11-04 2010-05-25 Forhumantech. Co., Ltd. Methods for treating rheumatoid arthritis using a CTLA-4 fusion protein
US20080132450A1 (en) * 2006-08-29 2008-06-05 Forhumantech. Co., Ltd. Pharmaceutical composition for suppression of apoptosis and method for delivering the same

Similar Documents

Publication Publication Date Title
JP2009544688A5 (enExample)
TWI480069B (zh) 用以改善心肌梗塞之醫藥組成物
RU2582247C2 (ru) Ингибиторы апоптоза и их применение
ES2632553T3 (es) Novedosos agonistas de receptor tipo 2 de angiotensina (AT2) y sus usos
JP2022520193A (ja) Cnpコンジュゲートの乾燥医薬製剤
CN110114065A (zh) 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生
HUP0303763A2 (hu) A trombinnal aktiválható fibrinolízist gátló (TAFIa-gátló) szubsztituált imidazolok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JP2012518636A (ja) 神経ペプチドy受容体結合化合物を有する細胞毒性コンジュゲート
WO2016118577A1 (en) Thymosin-beta-four fusion proteins
US11370816B2 (en) Histatins and method of use thereof
WO2007009359A1 (en) Thymosin beta 4 derivatives and use thereof
KR101746749B1 (ko) 뇌졸중-유발된 혈관신생 증진제 및 이의 용도
EA201791668A1 (ru) Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада
US20160168210A1 (en) Derivatives of collagen-binding hairpin peptides
JP2025521751A (ja) コラーゲンペプチドベースの医薬組成物及びその使用
CN106063928B (zh) 一种多肽或其衍生物在治疗高血压性心肌肥厚中的应用
JP2006516287A (ja) Mntfペプチドおよび組成物ならびに使用の方法
WO2019106680A1 (en) Treatment of an ischemic heart disease
KR20190050277A (ko) 허혈성 심혈관 질환의 치료용 또는 예방용 약학 조성물
CN112390877B (zh) Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用
JP7791593B2 (ja) 細胞透過性ペプチド変異体およびその用途
JPWO2021119756A5 (enExample)
JP2025532522A (ja) 新規血小板由来増殖因子ペプチド模倣物
JP2004513059A (ja) ペプチド産物、方法及び組成物
JP2025522281A (ja) Cnp化合物の液体医薬製剤